IGF1R and Graves ophthalmopathy: Anti-IGF1R MABs have not achieved regulatory approval for any malignant diseases, and their only current clinical indication is for the treatment of thyroid-associated ophthalmopathy [also known as Graves’ ophthalmopathy/orbitopathy or thyroid eye disease] for which teprotumumab (R1507) received FDA approval in 2020 (Douglas et al., 2020; Winn & Kersten, 2021).